← Human Trials & Peer-Reviewed Studies
Zinc-α2-glycoprotein is associated with insulin resistance in humans and is regulated by hyperglycemia, hyperinsulinemia, or liraglutide administration: cross-sectional and interventional studies in normal subjects, insulin-resistant subjects, and subjects with newly diagnosed diabetes
Plain-language guide to PMID 23275352 (2013): randomized controlled trial study of Liraglutide, insulin resistance, prediabetes & type 2 diabetes.
Key Facts
- PMID
- 23275352
- Journal
- Diabetes care
- Year
- 2013
- Study type
- Randomized Controlled Trial
- Authors
- Yang M et al. (13 authors)
- DOI
- 10.2337/dc12-0940
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Liraglutide in the context of insulin resistance, prediabetes & type 2 diabetes, published as a randomized controlled trial.
Zinc-α2-glycoprotein (ZAG) has been proposed to play a role in the pathogenesis of insulin resistance.
Previous studies in humans and in rodents have produced conflicting results regarding the link between ZAG and insulin resistance.
The objective of this study was to examine the relationships between ZAG and insulin resistance in cross-sectional and interventional studies.
Who Took Part
PubMed indexes the participants as adults, middle-aged adults and older adults, both men and women.
Serum ZAG (determined with ELISA) was compared with various parameters related to insulin resistance in subjects with normal glucose tolerance, impaired glucose tolerance (IGT), and newly diagnosed type 2 diabetes mellitus (T2DM), and in women with or without polycystic ovary syndrome (PCOS).
Euglycemic-hyperinsulinemic clamps were performed in healthy and PCOS women.
How the Study Was Run
The researchers set it up as a randomized study.
Random assignment meant chance, not the researchers, decided who got Liraglutide and who got the comparison, which limits bias.
What Was Measured
Topics PubMed links to this paper include Adipokines, Cross-Sectional Studies, Diabetes Mellitus, Type 2, Glucagon-Like Peptide 1, Hyperglycemia, Hyperinsulinism and Insulin Resistance.
What This Means in Plain Language
The paper is a randomized study of Liraglutide in people with insulin resistance, prediabetes & type 2 diabetes.
Its findings take up roughly 7 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.
The publication is from 2013 (Diabetes care), a journal based in United States.
More context: the Liraglutide compound page, Insulin resistance, prediabetes & type 2 diabetes research.
Our Notes on the Compound
Liraglutide: A once-daily GLP-1 receptor agonist peptide; sold as Victoza for type 2 diabetes and Saxenda for weight management.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.